Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Northern Trust Corp grew its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 28.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 318,177 shares of the company's stock after purchasing an additional 70,497 shares during the quarter. Northern Trust Corp owned approximately 0.85% of Entrada Therapeutics worth $5,501,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in TRDA. KLP Kapitalforvaltning AS acquired a new stake in shares of Entrada Therapeutics during the 4th quarter valued at approximately $36,000. Virtus ETF Advisers LLC purchased a new stake in Entrada Therapeutics during the fourth quarter worth $68,000. AlphaQuest LLC purchased a new position in shares of Entrada Therapeutics in the fourth quarter valued at $70,000. Russell Investments Group Ltd. raised its stake in shares of Entrada Therapeutics by 53,455.6% during the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after buying an additional 4,811 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Entrada Therapeutics during the 4th quarter worth $137,000. 86.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Tuesday, May 20th.

Entrada Therapeutics Stock Down 1.6%

Shares of NASDAQ:TRDA traded down $0.12 on Monday, reaching $7.50. 103,059 shares of the company's stock were exchanged, compared to its average volume of 130,987. The business's 50-day moving average is $8.57 and its two-hundred day moving average is $12.94. Entrada Therapeutics, Inc. has a fifty-two week low of $7.10 and a fifty-two week high of $21.79. The firm has a market capitalization of $284.65 million, a price-to-earnings ratio of 4.72 and a beta of 0.04.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.78) by $0.36. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. Analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.